학술논문
Three Months' PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736).
Document Type
Article
Author
Francolini, Giulio; Garlatti, Pietro; Di Cataldo, Vanessa; Detti, Beatrice; Loi, Mauro; Greto, Daniela; Simontacchi, Gabriele; Morelli, Ilaria; Burchini, Luca; Allegra, Andrea Gaetano; Frosini, Giulio; Ganovelli, Michele; Salvestrini, Viola; Olmetto, Emanuela; Visani, Luca; Becherini, Carlotta; Valzano, Marianna; Carnevale, Maria Grazia; Roghi, Manuele; Serni, Sergio
Source
Subject
*RESEARCH
*RADICAL prostatectomy
*CANCER relapse
*TREATMENT effectiveness
*CHOLINE
*TOXICITY testing
*RADIOSURGERY
*SALVAGE therapy
*PROSTATE-specific antigen
*COMPUTED tomography
*PROSTATE tumors
*LONGITUDINAL method
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: This article is a report about early toxicity and biochemical outcomes after stereotactic salvage radiotherapy for macroscopic recurrence within prostate bed after radical prostatectomy. Data reported suggest optimal tolerability profile and promising oncologic outcomes after this approach within a prospective multicentric trial. Biochemical recurrences after radical prostatectomy (RP) can be managed with curative purpose through salvage radiation therapy (SRT). RT dose escalation, such as stereotactic RT (SSRT), may improve relapse-free survival in this setting. STARR trial (NCT05455736) is a prospective multicenter study including patients affected by macroscopic recurrence within the prostate bed after RP treated with SSRT. Recurrence was detected with a Choline or PSMA CT-PET. In the current analysis, the early biochemical response (BR) rate and toxicity profile after three months of follow-up were assessed. Twenty-five patients were enrolled, and data about BR and toxicity at three months after treatment were available for 19 cases. Overall, BR was detected after three months in 58% of cases. Four G1–G2 adverse events were recorded; no G ≥ 3 adverse events were detected. SSRT appears feasible and safe, with more than half of patients experiencing BR and an encouraging toxicity profile. The STARR trial is one of the few prospective studies aimed at implementing this promising treatment strategy in this scenario. [ABSTRACT FROM AUTHOR]